Developmental stage modulates the prognostic impact of RAS pathway mutations in AML patients undergoing Allo-HSCT

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• RAS pathway mutations and developmental stage influence leukemic cell behavior.
• Their combined impact on acute myeloid leukemia (AML) prognosis post-allogeneic hematopoietic stem cell transplantation (allo-HSCT) is not well understood.

Purpose of the Study:

• To investigate the effects of RAS-pathway mutations and AML developmental stage on patient outcomes after allo-HSCT.
• To clarify the prognostic significance of RAS-pathway mutations in different AML subgroups.

Main Methods:

• Retrospective analysis of 364 adult AML patients undergoing first allo-HSCT with myeloablative conditioning.
• Detection of RAS-pathway mutations and assessment of cumulative incidence of relapse (CIR), overall survival (OS), and leukemia-free survival (LFS).

Main Results:

• RAS-pathway mutations were found in 15.7% of patients.
• In primitive AML, RAS mutations correlated with higher CIR (38.6% vs. 14.8%) and increased relapse risk (HR=2.55).
• In monocytic AML, RAS mutations were associated with lower CIR (3.4% vs. 26.8%) and improved LFS (93.1% vs. 66.9%, HR=0.23).

Conclusions:

• The prognostic impact of RAS-pathway mutations in AML patients undergoing allo-HSCT is critically dependent on the developmental stage of the leukemia.
• RAS mutations may portend a worse prognosis in primitive AML but a better prognosis in monocytic AML post-transplant.